NCT07216248

Phase 2Interventional

Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.

View on ClinicalTrials.gov ↗

Timeline

Start date: Oct 27, 2025
Primary completion: Oct 31, 2030
Completion date: Oct 31, 2031
First posted: Oct 14, 2025
Last posted: Oct 29, 2025
Enrollment: 160
Arms / groups: 3 / —
Source: AACT · ctgov ingestion

Drugs studied

relugolix

Indications studied

Prostatic Neoplasms

CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.

NCT07216248

Timeline

Sponsors

Drugs studied

Indications studied